Amgen nabs new Blincyto approval for certain type of leukemia
The FDA on Friday gave its stamp of approval to Amgen’s Blincyto to treat both adults and children with the most common type of acute …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
